120 Rue Albert Caquot
122 articles with MEDIAN Technologies
Median Technologies Has Been Confirmed as a Preferred Vendor by one of the Top 3 Pharmaceutical Companies in the World, and Selected to Implement Their Clinical Trial Imaging Strategy on Some Key Oncology Indications
Median Technologies (Paris:ALMDT) (ALMDT:PA) announced today that the company has been confirmed as a preferred vendor by one of the Top 3 pharmaceutical companies in the world and selected to implement their clinical trial imaging strategy on some key oncology indications.
Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort
Median Technologies announces outstanding performance based on a large-scale lung cancer screening patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
7/30/2021Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.
Median Technologies Appoints Jean-Christophe Montigny as Chief Financial Officer and Member of the Executive Committee
Median Technologies (Paris:ALMDT) today announces the appointment of Jean-Christophe Montigny as Chief Financial Officer.
Median Technologies, announces the publication date for its 2021 half year results and its Q3, 2021 business performance :
Median Technologies' Business Continues to Grow at a Steady Pace in the First Half of 2021 (Unaudited Figures)
For the first half of 2021, Median Technologies' revenue amounts to €10.1m, up 71% compared to the H1 2020 revenue, which stood at €5.9m.
Median Technologies Is Releasing Full Year 2020 Financial Results (audited) as Well as Q1 2021 Business Activity Indicators, Showing a Very Strong Growth
2020, a record year with revenue of €13.5m, up 51% on 2019 2020 results in line with expectations Acceleration of the growth dynamic in the first quarter of 2021 with revenue of €5.2m, an increase of 86% compared to Q1, 2020.
iBiopsy®: Median Technologies Continues Its Strong Positioning in Early-Stage Diagnosis with a New iBiopsy® Clinical Development Plan on Lung Cancer Screening (LCS)
Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions. The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide.
iBiopsy®: Median Technologies Inks a Major Research Collaboration Agreement With the University of California San Diego (UC San Diego)
The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsy®’s AI technology, applied to liver fibrosis characterization
2020 full year revenue of €13.5 million, increased by 51 % compared to 2019 (€9 million) As of December 31, 2020, order backlog of €51.7 million, up 35 % compared to December 31, 2019 Cash and cash equivalents of €16.3 million as of December 31, 2020
Median Technologies, The Imaging Phenomics Company® announces the publication date for its 2020 results
Revenues totalling €9.4m over the first three quarters 2020, higher than 2019 yearly revenue (€9m) Q3 revenue of €3.5m, a 50% increase compared to Q3, 2019 Order backlog of €50.7m Cash and cash equivalents of €17.3m
Revenue surges 47.9% compared with the first half of 2019 at €5.9m Order backlog up 40% over six months to €53.6m Cash and cash equivalents of €19.4m SOPHIA ANTIPOLIS, France--( BUSINESS WIRE )-- Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, today announced its results for the first half of 2020. On October 12, 2020, the Board of Directors of Median Technologies approved the consolidated fi
Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, announces the publication date for its half year results 2020: Publication Date 2020 half year results October 14, 2020* *Release after the close of trading About Median Technologies: Median Technologies provides innovative imaging solutions and servic
Half Year Median Technologies Liquidity Contract Statement Contracted with Louis Capital Markets UK LLP
Regulatory News: Under the liquidity contract entrusted by Median Technologies (Paris:ALMDT) (FR0011049824 – ALMDT FP) to Louis Capital Markets UK LLP, the following resources were listed in the liquidity account as of June 30, 2020: 32,518 shares €77,124.37 in cash Transactions during the first half 2020: BUY 114,265 shares 455,351.48 EUR
Regulatory News: Median Technologies (Paris:AMLDT), The Imaging Phenomics Company® (ALMDT) announced today that it has been awarded the Euronext European Rising Tech Label. The European Rising Tech Label recognizes 98 top-performing companies among more than 350 small and mi
Median Technologies (Paris:ALMDT), the Imaging Phenomics Company® announced today that Fredrik Brag, CEO of Median Technologies, will provide a company update on July 9th, 2020 at 11:00 am CEST during a webcast.
Median Technologies, the Imaging Phenomics Company® announced that Oern Stuge MD, MBA, has joined its Board of Directors, chaired by Oran Muduroglu.
6/18/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Median Technologies: iBiopsy®: Promising Results on a Preliminary Study to Evaluate the Risk of Tumor Recurrence in Patients With Primary Liver Cancer
Encouraging preliminary results about the iBiopsy® clinical development plan on liver cancer and the technological methods therein Development of a fibrosis biomarker from CT scan imaging A better performing biomarker compared to existing imaging biomarkers